ABSTRACT
INTRODUCTION
Occlusion of the central retinal artery can cause retinal ischemia, infarction, and acute vision loss [1] . Similar to ischemic cerebrovascular accidents, an embolic etiology is commonly from either a carotid artery or cardiac plaque, the latter often from atrial fibrillation [1, 2] . Recent studies have shown that the most meaningful risk factor for central retinal artery occlusion (CRAO) is an ipsilateral carotid artery stenosis; thus early imaging of the greater neck vessels is essential for management [3] . Ocular neovascularization (ONV) has been reported to occur in up to 19% of cases [4] [5] [6] [7] . This can involve neovascularization of the iris, the optic Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ FDB5F0601EE074E9. disc, or the surrounding retina. ONV onset following CRAO has been described anywhere from 2 weeks to 2 years after the original event, although the majority occur between 8 and 12 weeks afterward [6, 8] . ONV can further decrease vision and cause pain if neovascular glaucoma develops. Currently, there is a paucity of proven clinical treatments for CRAO. Treating CRAO with hyperbaric oxygen therapy (HBO) has been reported in animal studies and small series; however, we lack large controlled human studies [9] [10] [11] [12] [13] [14] . Its impact on downstream complications such as ONV is currently not well understood; thus, there is great interest in further investigation within this unique patient population.
CASE REPORT
A 70-year-old African male reported to the emergency department with decreased vision in the right eye (RE) and headache. His past medical history included hypertension, hyperlipidemia, diabetes mellitus, long-term poor vision in the left eye (LE) from previous ocular trauma, and pseudophakia of the RE. He described intermittent darkening of RE vision for the past 4 days along with a mild headache; however, he was able to read small print until 24 h prior to admission, when his RE vision decreased abruptly. He denied recent weight loss, fever, myalgia, or jaw claudication. He had an erythrocyte sedimentation rate of 32 mm/h (normal: 0-10 mm/h), C-reactive protein of 
DISCUSSION
ONV is a serious complication following CRAO with reported incidence ranging up to 19% [1] . A proposed mechanism of HBO therapy is that the elevated blood oxygen content achieved through HBO allows oxygen to diffuse more effectively into the retina from choroidal circulation. The inner retina that normally relies on central retinal artery perfusion receives sufficient oxygenation from both the choroidal vasculature and any residual retinal artery perfusion to survive until the central retinal artery recanalizes [15, 16] . This is predicated on applying the HBO while the retinal ischemia is still reversible, typically within the first 2 days after the inciting event.
The vision in our patient did improve with HBO, but remained poorer than it was prior to the CRAO, and far poorer than that of many other eyes at our institution that undergo prompt HBO therapy for CRAO. This was most likely due to our inability to fully reverse the initial ischemic retinal insult. He probably sustained a large component of irreversible macular ischemia from the series of transient amaurosis episodes and the 24 h of CRAO prior to onset of HBO therapy. This may well be the reason for his development of ONV and it would have happened regardless of whether he underwent HBO therapy. His ONV developed a little less than a month after the CRAO, within a time range that has certainly been reported after untreated CRAO, although it is on the earlier side of the spectrum.
A potential mechanism beyond just profound initial ischemia may involve the HBO therapy itself. The acute HBO protocol for CRAO at our institution during the time of this study included two treatments per day for a proposed by other groups [9, 12] . Even though the patient initially presented possibly outside of the 24 h treatment window, we felt compelled to offer HBO to provide as much potential as possible for him to recover vision in his RE in the monocular setting. ONV is driven by vascular endothelial growth factor (VEGF) released from ischemic retinal tissue that is not dead. When initial infarction occurs, the retina declines to an ischemic state, and VEGF begins to be released. Over time, the ischemic retina in an untreated patient declines further into necrosis and atrophy; thus, VEGF secretion is stopped. It is conceivable that in the HBO-treated patient, the ischemic phase is prolonged by the improvement in retinal oxygen saturation, thus enhancing VEGF release and potentially worsening ONV (Fig. 4) . Further clinical studies will be essential to further elucidate this process.
CONCLUSION
Ultimately, HBO remains a controversial treatment modality for CRAO, a condition for which we are still without a proven and widely Fig. 4 The proposed mechanism of VEGF elevation by HBO therapy in CRAO. After acute infarction, profound retinal ischemia induces a period of time where VEGF is released in response. While the untreated retina eventually declines into atrophy and death (dotted line), the HBO-treated retina is maintained in a prolonged ischemic state (solid line). This can promote prolonged VEGF release to result in a relatively quicker onset of ONV compared to the untreated retina. VEGF vascular endothelial growth factor, HBO hyperbaric oxygen therapy, CRAO central retinal artery occlusion, ONV ocular neovascularization
